tbuckley/cabot-search huggingface dataset:
Submassive Pulmonary Embolism
Authors: Parth M. Rali, Gerard J. Criner
Journal: American Journal of Respiratory and Critical Care Medicine (2018)

Pulmonary embolism (PE) presents a spectrum of hemodynamic consequences, ranging from being asymptomatic to a life-threatening medical emergency. Management of submassive and massive PE often involves clinicians from multiple specialties, which can potentially delay the development of a unified treatment plan. In addition, patients with submassive PE can deteriorate after their presentation and require escalation of care. Underlying comorbidities such as chronic obstructive pulmonary disease, cancer, congestive heart failure, and interstitial lung disease can impact the patient's hemodynamic ability to tolerate submassive PE. In this review, we address the definitions, risk stratification (clinical, laboratory, and imaging), management approaches, and long-term outcomes of submassive PE. We also discuss the role of the PE response team in management of patients with PE.
Sphingolipids: a further step into the detection of early and intermediate hepatocellular carcinoma
Authors: I. Nenu, C. Hebristean, P. Fisher, A. Suciu, H. Stefanescu, B. Procopet, D. Liliana, A. Cavasi, A. Seicean, Z. Sparchez, M. Tantau, C. Socaciu, M. Grigorescu
Journal: Journal of Hepatology (2018)
A new perspective on lipid research in age-related macular degeneration
Authors: Elisabeth M. van Leeuwen, Eszter Emri, Benedicte M.J. Merle, Johanna M. Colijn, Eveline Kersten, Audrey Cougnard-Gregoire, Sascha Dammeier, Magda Meester-Smoor, Frances M. Pool, Eiko K. de Jong, Cécile Delcourt, Eduardo Rodrigez-Bocanegra, Marc Biarnés, Philip J. Luthert, Marius Ueffing, Caroline C.W. Klaver, Everson Nogoceke, Anneke I. den Hollander, Imre Lengyel
Journal: Progress in Retinal and Eye Research (2018)

There is an urgency to find new treatment strategies that could prevent or delay the onset or progression of AMD. Different classes of lipids and lipoproteins metabolism genes have been associated with AMD in a multiple ways, but despite the ever-increasing knowledge base, we still do not understand fully how circulating lipids or local lipid metabolism contribute to AMD. It is essential to clarify whether dietary lipids, systemic or local lipoprotein metabolismtrafficking of lipids in the retina should be targeted in the disease. In this article, we critically evaluate what has been reported in the literature and identify new directions needed to bring about a significant advance in our understanding of the role for lipids in AMD. This may help to develop potential new treatment strategies through targeting the lipid homeostasis.
A phase I/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed/refractory multiple myeloma (MM).
Authors: Jesus G. Berdeja, Tara K. Gregory, Jeffrey Matous, Lowell L. Hart, Rami Owera, Joseph Ronald Mace, James H. Essell, Ian Flinn, Edward Anthony Faber
Journal: Journal of Clinical Oncology (2015)

8513 Background: Histone deacetylase inhibitors (HDACi) and proteasome inhibitors (PI) act synergistically through inhibition of the proteasome and aggresome pathways. We have previously reported the combination of the HDACi, PAN and the PI, CFZ in pts with relapsed and relapsed/refractory MM with encouraging results (Blood 2013;122:1937). The maximum tolerated dose (MTD) of CFZ and PAN was never reached and we extended our original study to investigate higher dose levels. Here we present the preliminary results of this ongoing trial. Methods: Pts with MM who relapsed after ≥ 1 prior treatment were eligible. PAN was administered orally on D 1, 3, 5, 15, 17, 19 of each 28-day cycle. CFZ was administered IV over 30 min on D 1, 2, 8, 9, 15, and 16. The maximum planned dose (MPD) from the original study was 30 mg PAN plus 20/45 mg/m2 CFZ, so we next escalated to 30 mg PAN plus 20/56 mg/m2 CFZ. Due to numerous PAN dose reductions in the previous cohorts, we explored PAN at 20 mg and CFZ 20/56 mg/m2. Treatment continued until PD or intolerable toxicity. The primary efficacy endpoint was the overall response rate (ORR) ( ≥ PR). AEs were assessed according to CTCAE v 4.0 and responses were assessed using IMWG criteria (plus MRs as per the EBMT criteria). Results: As of the data cutoff (12/2014), 26 pts (median age 62 (range 49-91), 39% poor risk FISH) were enrolled. Pts had a median of 3 (range 1-9) prior therapies including 69% with prior PI, 58% with prior IMiDs and 50% with prior stem cell transplants. 27% were refractory to either IMiDs or PIs, and 26% were refractory to their last treatment regimen. There were no DLTs, but based on PAN dose reductions observed in the previous cohorts, the 20 mg PAN plus 20/56 CFZ dose level was expanded and 23 of the 26 enrolled pts were treated at this dose level. 12 (57%) pts remain on active treatment. The most common related ≥ grade (G) 3 hematologic AEs was thrombocytopenia, (31%) and the most common ≥ G3 non hematologic AEs included, fatigue (4%)and diarrhea (4%). The ORR was 82% with 34% ≥ VGPR and 48% PR. The clinical benefit rate was 91%. Conclusions: The combination of PAN 20mg and CFZ 20/56 in this schedule is safe and effective in this relapsed/refractory MM population. Clinical trial information: NCT01496118.
Risk of de novo hepatocellular carcinoma after DAA treatment within two years following treatment with Ombitasvir/Paritaprevir/ritonavir ± Dasabuvir ± Ribavirin in the AMBER – real world experience study
Authors: R. Flisiak, M. Łucejko, D. Zarebska-Michaluk, K. Tomasiewicz, K. Rostkowska, M. Tudrujek, M. Grzegorz, S. Krzysztof, J. Biatkowska, M. Jablkowski
Journal: Journal of Hepatology (2018)
P458Cardiac fibroblasts as inflammatory supporter cells trigger cardiac inflammation in heart failure - Influence of Heart Rate on Pathophysiological Fibroblast Activation
Authors: D Lindner, S Hinrichs, J Schoen, F Gotzhein, M Scwarzl, S Blankenberg, U Voelker, E Hammer, D Wstermann
Journal: Cardiovascular Research (2018)

Materials and methods of research.The study included 19 patients with primary a STEMI the average age was 59 6 17 years.All patients underwent PCI with reperfusion of the infarctionrelated coronary artery.The mean recanalization time was 5 (4, 6) h.Using EchoCG, final systolic volume (CSR), terminal diastolic volume (BWW), LV ejection fraction (LVEF) was msured admission, 3rd, 7th and 21st day of STEMI.The CD133þ cells level was determined by flow cytometry of venous blood samples in the same periods.There was a control group of healthy volunteers (6 males) the average age was 41 6 9 years (absolutely healthy).Results: Carrying out an individual analysis of CD 133þ cells level circulating in patients with acute myocardial infarction, they found a multidirectional, nonlinear dynamics of their content by the 3rd day of MI.Due to this dynamics, all patients were divided into 2 subgroups: the 1st subgroup consisted of the patients with initially low level and it's further increasing on the 3rd day of MI, the 2nd subgroup -patients with a decrease level to a 3-m day of illness.Intragroup and intergroup differences were revealed on different days of the disease (p <0.05).A positive correlation was established between the relative amount of CD133þ cells in patients of the 2nd subgroup on the 7th day of MI and LVEF on the 21st day (R ¼ 0.7, p ¼ 0.02).Also, a relationship was found between the low absolute amount of CD 133þ cells in the first day of acute myocardial infarction and signs of chronic heart failure (CHF) after 6 months of the disease (p <0.05).Namely: in patients of the first subgroup, 6 months after of acute MI, minimal clinical manifestations of CHF were observed.This fact confirms that a high release of CD133þ cells into the peripheral channel is associated with a favorable course and disease prognosis. Conclusion:We showed the response of marrow to acute myocardial infarction, as release of CD133þ cells into the blood.It was found that the high mobilization of these cells both on the 1st day of MI and during the whole observation period was associated with a favorable course and disease prognosis, according to improvement of clinical and echocardiographic parameters.
Durable inhibition of hepatitis B virus replication and antigenemia using a subcutaneously administered siRNA agent in preclinical models
Authors: A.C.H. Lee, J. Heyes, X. Ye, R. Holland, E.P. Thi, M. Wood, A. Judge, N.M. Snead, A. Martin, M.J. Sofia
Journal: Journal of Hepatology (2018)
Radial-Artery or Saphenous-Vein Grafts in Coronary-Artery Bypass Surgery
Authors: Mario Gaudino, Umberto Benedetto, Stephen Fremes, Giuseppe Biondi-Zoccai, Art Sedrakyan, John D. Puskas, Gianni D. Angelini, Brian Buxton, Giacomo Frati, David L. Hare, Philip Hayward, Giuseppe Nasso, Neil Moat, Miodrag Peric, Kyung J. Yoo, Giuseppe Speziale, Leonard N. Girardi, David P. Taggart
Journal: New England Journal of Medicine (2018)

The use of radial-artery grafts for coronary-artery bypass grafting (CABG) may result in better postoperative outcomes than the use of saphenous-vein grafts. However, randomized, controlled trials comparing radial-artery grafts and saphenous-vein grafts have been individually underpowered to detect differences in clinical outcomes. We performed a patient-level combined analysis of randomized, controlled trials to compare radial-artery grafts and saphenous-vein grafts for CABG.
Outcomes of direct-acting antiviral therapy for chronic hepatitis C following unrestricted access in Australia: Real-world outcomes from the state of South Australia
Authors: J. Haridy, A. Wigg, K. Muller, J. Ramachandran, E. Tilley, V. Waddell, D. Gordon, D. Shaw, D. Huynh, J. Stewart, R. Nelson, M. Warner, M. Boyd, A. Chinnaratha, D. Harding, L. Ralton, A. Colman, G. Iyngkaran, E. Tse
Journal: Journal of Hepatology (2018)
The effect of intragastric balloon therapy on the intestinal microbiome in obese patients with non-alcoholic fatty liver disease, and correlations with anthropometric indices, nutritional factors, and serum immunological markers
Authors: V.I. Nguyen, P. Cordero, J. Li, C. Katar, C. Blumenthal, V. Male, A. Cuff, A. Wijeyesekera, J. Mcdonald, A. Perdones-Montero, E. Holmes, J. George, J.A. Oben
Journal: Journal of Hepatology (2018)
Prediction of fibrosis improvement in patients with advanced fibrosis due to NASH using a machine learning approach: Unravelling the placebo response
Authors: A. Sanyal, T. Nguyen, L. Wang, Y. Xiao, C. Jia, R. Xu, S. Djedjos, M. Subramanian, R. Myers, V. Ratziu, N. Afdhal, J. Bosch, S. Harrison, Z. Goodman
Journal: Journal of Hepatology (2018)
Bone metastases (BM) in patients (pts) with locally advanced or metastatic gastric cancer (AGC): Clinical and therapeutic implications.
Authors: Wanda Liguigli, Laura Toppo, Gianluca Tomasello, Rossana Poli, Margherita Ratti, Silvia Lazzarelli, Bianca Maria Donida, Rodolfo Passalacqua
Journal: Journal of Clinical Oncology (2014)

e15006 Background: At diagnosis BM occur in approximately 10-15% of AGC pts and their prognosis is poor (Park 2011; Silvestris 2013). Aim of this study is to identify the main features of pts with AGC and BM at diagnosis together with their response to chemotherapy and clinical course. Methods: We reviewed the clinical records of all AGC pts followed at Cremona Oncology Division from November 2004 to January 2013 and included in three consecutive prospective trials (Dalla Chiesa M. 2011; Tomasello G. 2013). We compared pts with BM at diagnosis vs pts without BM. All pts received a first linetherapy with TCF-dd regimen + Pegfilgrastim. Baseline clinical and pathological parameters were evaluated, together with Overall Survival (OS), Response Rate (RR), Time to Progression (TTP), Time From first Progression to Death (TFPTD), and toxicity. Analysis was based on the intention to treat principle. Results: 151 AGC pts were identified: 21 with BM and 130 without BM.The presence of non-bone metastases was balanced between the two groups. Main pts characteristics and results are reported in the Table below. Conclusions: In pts with AGC the presence of BM at diagnosis is not a rare event and identifies a population with a very poor outcome. The incidence of coagulation disorders is definitely higher, the TFPTD is dramatically shorter and hematological toxicity can be relevant and requires a careful monitoring. We need new strategies for this population. BM # Median age, yrs ECOG PS ≥ 2 DIC ORR TTP months OS months TFPTD months Hemathological toxicity Grade 3-4 No 130 66 13 (10%) 1 (<1%) 56% 8 (CI 95% 6.4-10) 12.7 (CI 95% 9.7-14.7) 3.2 Neutrophil 43 (34%) Hb 9 (7%) Platelet 18 (14%) Yes 21 57 5 (24%) 5 (24%) 52% 7.1 (CI 95% 2.6-11) 7.8 (CI 95% 3.8-10) 1.2 9 (43%) 6 (28%) 8 (38%) P P<0.001 P=0.15 P=0.0001 P=0.012 P=0.22 P=0.001 P=0.07 P=0.0024 P=0.176 P=0.074 Abbreviations: BM, bone metastases; DIC, disseminated intravascular coagulation; ORR, overall response rate; TTP, time to progression; TFPTD, time from first progression to death.
DNA damage repair (DDR) pathway defects in gastrointestinal (GI) malignancies.
Authors: Ramya Thota, Gail Fulde, Mark Andrew Lewis, Derrick S. Haslem, Lincoln Nadauld, Bryce Moulton, Robin Romero, Tyler Abraham, Bryce Christensen, Sharanya Raghunath, Tyler Barker
Journal: Journal of Clinical Oncology (2018)

647 Background: The clinical significance of the genomic alterations associated with DDR pathway in GI tumors (besides MMR defects) is largely unknown. These patients can potentially derive benefit from targeted therapy with poly ADP ribose polymerase (PARP) inhibitors, which have already shown promising activity in ovarian, breast and prostate cancers. In this study, we investigated the frequency and clinical significance of DDR repair defects (other than MMR defects) in GI tumors. Methods: We performed a retrospective analysis of all patients who had tumor next generation sequencing performed between January 2013 and August 2017 on GI cancers harboring DDR pathway defects. Data including demographics, clinical history, and treatment were extracted from patients' records. Results: Of 299 patients with GI tumors sequenced, 35 cases (12%) were noted to have DDR defects. The most commonly mutated genes – 6 (17%) BRCA2, 5 (14%) PALB2, 4 (11%) ATM, 3 (8.6%) BRCA1, 2 (5.7%) each of NBN, MUTYH, ERCC3, PARP1 amplification and 1 (2.8%) each of ERCC2, CDK12, and PARP2 amplification. Two patients had both ATM and BRCA2 mutations. Combination of ATM and MRE11, ATM and BRCA1, BRCA1 and ERCC6, BRCA2 and CDK12 were noted in 1 patient each. Of the 23 patients with available clinical data, the median age at diagnosis was 65 (range 30–85) years with male and female prevalence rates of 60.8% and 39.2%, respectively. Stage at diagnosis was I (n = 3), II (n = 3), III (n = 8), and IV (n = 9). The primary site of tumor was found in 8 (34.8%) colon, 4 (17.4%) liver, 4 (17.4%) pancreas, 2 (8.7%) esophagus, 2 (8.7%) anus, 2 (8.7%) appendix, 1 (4.3%) rectum. Seventeen patients received platinum‐based therapy, 7 were treated with PARP inhibitors and 5 patients received both platinum and PARP inhibitor. Median overall survival from diagnosis for patients with stage I/II was 65.3 months, stage III was 23.1 months, and stage IV was 22.4 months. The median survival of patients treated with olaparib was 24.5 months. Conclusions: DDR pathway defects in GI tumors are uncommon. However, they can potentially be targeted with PARP inhibitors with durable survival. Future clinical trials are warranted to explore the role to PARP inhibitors in these unique subset of patients.
Hepatic differentiationof human induced pluripotent stem cells (iPSC) using 3D human liverextracellular matrix hydrogel
Authors: L. Frenguelli, R. Tomaz, W. Al-Akkad, M. Najimi, E. Sokal, M. Pinzani, L. Vallier, G. Mazza
Journal: Journal of Hepatology (2018)
EVALUATION OF MEAN ADENOMAS PER COLONOSCOPY AND ADENOMAS PER POSITIVE PARTICIPANT AS NEW QUALITY PARAMETERS IN SCREENING COLONOSCOPY
Authors: I Gessl, E Waldmann, D Penz, B Majcher, A Dokladanska, A Hinterberger, A Szymanska, M Trauner, M Ferlitsch
Journal: Endoscopy (2018)

The adenoma detection rate (ADR) is widely accepted as one of the main quality parameters in screening colonoscopy. However, the question arises whether the detection of further adenomas after the first should be monitored. The primary aim of this study was to correlate adenomas per positive participant (APP) and mean adenomas per colonoscopy (APC) with the ADR, advanced ADR (AADR) and the detection rate of serrated adenomas (SDR). Furthermore, we wanted to assess if these parameters differ depending on the setting or profession.
Propranolol Versus Metoprolol for Treatment of Electrical Storm in Patients With Implantable Cardioverter-Defibrillator
Authors: Sofia Chatzidou, Christos Kontogiannis, Diamantis I. Tsilimigras, Georgios Georgiopoulos, Marinos Kosmopoulos, Elektra Papadopoulou, Georgios Vasilopoulos, Stylianos Rokas
Journal: Journal of the American College of Cardiology (2018)
Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort
Authors: Sebastian M Waszak, Paul A Northcott, Ivo Buchhalter, Giles W Robinson, Christian Sutter, Susanne Groebner, Kerstin B Grund, Laurence Brugières, David T W Jones, Kristian W Pajtler, A Sorana Morrissy, Marcel Kool, Dominik Sturm, Lukas Chavez, Aurelie Ernst, Sebastian Brabetz, Michael Hain, Thomas Zichner, Maia Segura-Wang, Joachim Weischenfeldt, Tobias Rausch, Balca R Mardin, Xin Zhou, Cristina Baciu, Christian Lawerenz, Jennifer A Chan, Pascale Varlet, Lea Guerrini-Rousseau, Daniel W Fults, Wiesława Grajkowska, Peter Hauser, Nada Jabado, Young-Shin Ra, Karel Zitterbart, Suyash S Shringarpure, Francisco M De La Vega, Carlos D Bustamante, Ho-Keung Ng, Arie Perry, Tobey J MacDonald, Pablo Hernáiz Driever, Anne E Bendel, Daniel C Bowers, Geoffrey McCowage, Murali M Chintagumpala, Richard Cohn, Timothy Hassall, Gudrun Fleischhack, Tone Eggen, Finn Wesenberg, Maria Feychting, Birgitta Lannering, Joachim Schüz, Christoffer Johansen, Tina V Andersen, Martin Röösli, Claudia E Kuehni, Michael Grotzer, Kristina Kjaerheim, Camelia M Monoranu, Tenley C Archer, Elizabeth Duke, Scott L Pomeroy, Redmond Shelagh, Stephan Frank, David Sumerauer, Wolfram Scheurlen, Marina V Ryzhova, Till Milde, Christian P Kratz, David Samuel, Jinghui Zhang, David A Solomon, Marco Marra, Roland Eils, Claus R Bartram, Katja von Hoff, Stefan Rutkowski, Vijay Ramaswamy, Richard J Gilbertson, Andrey Korshunov, Michael D Taylor, Peter Lichter, David Malkin, Amar Gajjar, Jan O Korbel, Stefan M Pfister
Journal: The Lancet Oncology (2018)

Medulloblastoma is associated with rare hereditary cancer predisposition syndromes; however, consensus medulloblastoma predisposition genes have not been defined and screening guidelines for genetic counselling and testing for paediatric patients are not available. We aimed to assess and define these genes to provide evidence for future screening guidelines.
Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials
Authors: Srinivasan Beddhu, Tom Greene, Robert Boucher, William C Cushman, Guo Wei, Gregory Stoddard, Joachim H Ix, Michel Chonchol, Holly Kramer, Alfred K Cheung, Paul L Kimmel, Paul K Whelton, Glenn M Chertow
Journal: The Lancet Diabetes & Endocrinology (2018)
Mitochondria-targeted prostate cancer therapy using a near-infrared fluorescence dye–monoamine oxidase A inhibitor conjugate
Authors: Qingzhi Lv, Xiaoguang Yang, Menglin Wang, Jincheng Yang, Zhilin Qin, Qiming Kan, Haotian Zhang, Yongjun Wang, Dun Wang, Zhonggui He
Journal: Journal of Controlled Release (2018)
P156Genetic causes of hypercholesterolaemia among participants of epidemiological study
Authors: N Shcherbakova, A Ershova, A Zharikova, A Kiseleva, S Shalnova, S Boytsev, O Drapkina, A Meshkov
Journal: Cardiovascular Research (2018)

genotypes of hemostatic system.One patient (2,3%) had unfavorable heterozygous genotypes according to 5 studied variants predisposing to the development of thrombophilia; 8 (18%) had heterozygous genotypes of 4 SNP, 14 (32%) had heterozygous genotypes of 3 SNP, 14 (32%) had 2 SNPs, 4 (9% ) -1 SNP; only three (7%) individuals did not have adverse heterozygous alleles.The frequency of registration of genotypes predisposing to thromboses shown in table.At the same time, data are available on the prevalence of alleles 5G and 4G polymorphic variant of the PAI-1 gene in healthy adolescents in Russia.In particular, heterozygous genotypes of homozygotes both at the 5G allele and 4G allele are less frequently detected in patients with NOCA, and 5G / 4G are more often detected. Conclusion:The proportion of patients with NOCA among patients with ACS in 2015-2016 was 4.8%.The frequency of adverse allelic variants hemostatic gene polymorphisms associated with risk of thrombophilia in patients with ACS and NOCA was 98%.
TCTAP C-101 Ping-pong Technique for CTO
Authors: Minsoo Kim, Sangwoo Park, Sun Hack Lee, Tae-Oh Kim, Yong-Hoon Yoon, Sang Yong Om, Hanbit Park, Sang-Cheol Cho, Kyusup Lee, Osung Kwon, Pil Hyung Lee, Jung-Min Ahn, Soo-Jin Kang, Duk-Woo Park, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2018)
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) to predict better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients.
Authors: Giovanni Brandi, Simona Tavolari, Francesco Vasuri, Andrea Farioli, Marzia Deserti, Giorgio Frega, Jodi Corbelli, Maria aurelia Barbera, Maria A. Pantaleo, Stefania Di Girolamo, Guido Biasco
Journal: Journal of Clinical Oncology (2013)

e15003 Background: The role of adjuvant chemotherapy in CC is controversial and, to date, no standard treatment has been established in this setting. Some institutions offer gemcitabine (GEM) as adjuvant strategy to radically resected CC patients. The efficient uptake of this drug into cells requires the expression and plasma membrane localization of hENT-1. A recent study showed that a high hENT-1 expression closely associated with better survivals in macroscopically (R0 + R1) resected CC patients treated with adjuvant GEM plus S-1. In the present study, we analyzed the relationship between hENT-1 expression/localization and disease free survival (DFS) in CC patients undergone surgery and treated with adjuvant GEM. Methods: A total of 71 CC patients (44 intra-hepatic and 27 extra-hepatic) operated between 2002 and 2011 (46 R0 and 25 R1) and treated with adjuvant GEM (1000 mg/m 2 , 1-8-15/21 days planned for 6 months) in our institution were enrolled and retrospectively analyzed for hENT-1 expression/localization by immunohistochemistry. Main outcome measure was DFS. Hazard ratios (HR) of relapse and associated 95% confidence intervals (95% CIs) were obtained from proportional hazards regression models stratified on quintiles of propensity score (estimated from baseline covariates). Results: 26/71 patients (36.6%) showed a high hENT-1 plasma membrane expression. During a median follow-up of 18.1 months (IQR 9.1–36.2) 49 relapses were observed. Patients with a high expression of hENT-1 showed a reduced risk of relapse (HR 0.50, 95%CI 0.26–0.99, p=0.047). Noteworthy, the effect of hENT-1 appeared to increase across tertiles of duration of gemcitabine-based adjuvant chemotherapy (lower tertile, ≤102 days: HR 0.87, 95%CI 0.30–2.53; middle tertile, 103–170 days: HR 0.68, 95%CI 0.22–2.06; higher tertile, ≥171 days: 0.20, 95%CI 0.04–0.94). Conclusions: High plasma membrane hENT-1 expression was associated with a longer DFS among CC patients. The interaction between hENT-1 expression and duration of chemotherapy deserves further investigations, as it could be useful to tailor optimal GEM-based adjuvant chemotherapies.
Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade
Authors: Cecile A.W. Geuijen, Camilla De Nardis, David Maussang, Eric Rovers, Tristan Gallenne, Linda J.A. Hendriks, Therese Visser, Roy Nijhuis, Ton Logtenberg, John de Kruif, Piet Gros, Mark Throsby
Journal: Cancer Cell (2018)